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Summary A modified tetrazolium reduction assay (MTT) was used to assess the relation between HLA class
I antigen expression on tumour cells and their susceptibility as a target for non-MHC restricted LAK/NK
cytotoxicity using interleukin-2 activated peripheral blood mononuclear cells (MNC) from normal individuals.
At 20/1 effector/target ratio this ranged from no killing to 77%. The efficiency of killing was dependent on
duration of effector cell culture with IL-2, peaking at day 10 and declining thereafter. This killing could be
enhanced by addition of other cytokines including interferons alpha, beta and gamma.
Study of a panel of 15 tumour cell lines using a single effector showed that there was no statistically
significant inverse correlation (using Spearman rank test) between the degree of tumour class I expression and
LAK/NK killing at 20/1 (r = 0.23 P = 0.39) and 10/1 (r = 0.30, P = 0.27) and at 5/1 E/T ratio r = 0.47,
P = 0.08) respectively. Lack of inverse correlation between these two parameters came from study of one
bladder tumour line (FEN), whose absent class I antigens had been corrected by transfection with P2
microglobulin gene. At high E/T ratio (20/1) there was an increase in the susceptibility of target cells to lysis
(36% parent cell, 45% transfected cell), whilst at lower E/T ratios (1/1) there was significantly more killing of
the non-transfected cells (10% vs 31%). The addition of anti-class I antibody W6/32 increased killing by 18%
but this was non-specific as the same increase occurred with a class II antibody.
These data suggest that overall there was not an inverse correlation between class I expression and
LAK/NK killing at high E/T ratios, whilst at low (5/1 or lower) E/T ratios this correlation nearly reached
statistical significance suggesting that the conflicing literature reports may be due to a threshold levels of
effector cells above which the masking effects of MHC antigens disappears.
There is increasing recognition that abnormalities in Major
Histocompatibility Complex (MHC) antigens may be a factor
for tumour escape from immunosurveillance (for review see
Oliver & Nouri, 1992). Reports suggesting that correction of
these defects in tumour cells either by cytokine gene transfec-
tion (Gansbacher et al., 1990) or MHC gene transfection
(Hui et al., 1984) induced immunity in recipients that enables
them to reject parental untransfected tumour cells, offer real
hope that genetic engineering could provide a cost effective
approach to treatment of cancer.
Critical to the hypothesis of primacy of T cell immunity in
resistance to cancer is the occurrence of specific MHC
restricted anti-tumour cytolytic T lymphocytes (CTL).
Though these can be demonstrated in a minority of melano-
mas with apparently normal class I expression but over
expression of non-functioning class II (Alexander et al., 1989)
and the occasional other tumour under certain conditions
(Lee et al., 1978; Belldegrun et al., 1988), most adult solid
tumour patients only show lymphokine activated killer
(LAK) and natural killer (NK) cytotoxicity (Itoh et al., 1988;
Nouri et al., 1991) possibly a reflection of their degree of
aberrant class I expression.
NK activity was first described by Kiessling et al. (1975).
Because some tumour cells, such as Daudi were consistently
resistant to NK cytotoxicity, it was the discovery that IL-2
activated lymphocytes were cytotoxic for Daudi that led to
the definition of LAK cells (Grimm et al., 1982). It is now
thought that LAK represents an activated form of NK cyto-
toxicity (Lange et al., 1991) and are involved in protection
against experimental animal tumours (Mule et al., 1984) and
in leukaemia in man (Archimbaud et al., 1991).
There has been considerable controversy over the influence
of class I antigen on LAK/NK killing. Some authors (Karre
et al., 1986; Lobo & Spencer 1989; Maziarz et al., 1990) have
demonstrated an inverse correlation, while others (Pena et
al., 1989) failed to confirm these observations.
To clarify these conflicting views LAK/NK activity of cells
from normal individuals activated with IL-2 against a series
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of cell lines with varying degrees of class I antigens was
investigated together with a study of the effect of correcting
HLA class I defect on class I negative tumour line by gene
transfection.
Materials and methods
Interferons, monoclonal antibodies, plasmids and cell lines etc
Interferon a, P and y were obtained from Wellcome, ASTA
Pharma (Bioferon) and Biogen respectively. Monoclonal
antibodies (Mabs) were W6/32 (Brodsky et al., 1979, detects
all P2m-associated HLA-A,B,C antigens) and L243 (HB55,
Lampson & Levy 1980, detects class II antigens). The pp2m-
13 plasmid contains P2-m gene and was kindly donated by
Dr E.J. Baas (Dept Cellular Biochemistry, The Netherlands
Cancer Institute) and marker gene pSV2neo by Dr G.
Reynolds, Cancer Immunology Laboratory, ICRF, Oxford).
Cell lines Fen, Ha and Lan were in-house established lines
from tumour biopsies of patients with transitional cell car-
cinoma, teratoma and seminoma respectively. For cell lines
J82, Wil, RT4, Scaber, RT112, Tera I, Tera II, EP2012,
5637, SKV14 and lines see reference (Nouri et al., 1992a), for
MCF7 from Human cell culture Bank (Mason Research inst.
Rockville, MD, USA), T47D from ECACC (catalogue No.
85102201) and A431 from ATCC (CRL1555). Optimem and
Lipofectin for transfection were purchased from Gibco (Cat
No. 041-01985H) and BRL (Cat No. 8292 SA) respec-
tively.
Preparation ofMNCs and development ofIL-2-activated cells
or TILs
The MNCs from normal individuals were separated using
density gradient technique (Lymphoprep, Nycomed,
Pharma), as described previously (Nouri et al., 1991). The
interface cells were aspirated washed and stimulated with
IL-2 (100 uml-', Biogen) for 72-96 h (unless otherwise
stated) at 37°C. These activated cells, which are known to
have both LAK and NK activities, were washed and resus-
pended at the required density to be used as effector cells (E).
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Tumour infiltrating lymphocytes (TILs) were isolated from
tumour biopsies as described previously (Nourn et al., 1991).
Briefly, suspension of single cells prepared from tumours
were prepared immediately after operation and after washes
the cells were activated with IL-2 (100 u ml-') and cultured.
The TILs from successful cases were fed every 2 to 3 days by
adjusting the cell number to 0.5 x 106rml` in RPMI plus
10% Foetal Calf Serum (FCS, Gibco) and IL-2 (100 u
ml-).
Binding assay
Tumour cells i.e. target (1 x 104/well) were treated with inter-
ferons (IFN) a (1,000uml-1), 13 (2,000uml-') or IFN y
(100 yt ml-') for 48 h (conditions which have previously been
found to be optimum for maximum class I and II antigen
induction, (Nourn et al., 1992b), in flat-bottomed microtitre
plates and appropriate concentration of specific monoclonal
antibodies containing 0.02% sodium azide (50 pl/well, in
three replicates) were added and incubated for 45 mins at
room temperature (RT). After three washes, 50pl of diluted
(in RPMI plus 10% FCS and 0.02% azide) iodinated rabbit-
anti-mouse antibody (50,000 cpm/well, Amersham) was add-
ed and incubation continued for a further 45 min. Following
three washes, the cells were lysed with 100ftl/well of 2% (v/v)
triton x 100 in water and the degree of radioactivity in the
supernatants was measured using a gamma counter.
CYtotoxicitY using MTT reduction assai'
The use of MTT reduction assay for assessment of cytotox-
icity has previously been reported (Hussain et al., 1992). This
was carried out using the modified MTT (3-[4,5-Dimethyl-
thiazol-2yl]-2,5 diphenyl tetrazolium bromide) assay describ-
ed by Mosmann (1983). Exponentially growing cells were
treated with trypsin (0.05%) + EDTA (0.02%) for 5 min,
washed resuspended in RPMI containing 10% FCS and
plated at 10 x 103/well in flat-bottomed microtitre plates
(Nunc). Effector cells i.e. IL-2-activated MNCs were added
to give effector/target (E/T) ratios of 5/1, 10/1 or 20/1 and
were incubated for 4 h at 37°C. After incubation, plates were
washed with fresh medium plus 2% FCS and the remaining
cells were loaded with 10Al/well of 5 mg ml- MTT plus
100Al/well of medium and incubated for 3 h at 37°C. After
the incubation medium was removed and 100 Al of acidified
(0.04 M HCI) isopropanol was added, and the cells were
incubated for 30 min at RT followed by the reading of the
plate by an ELISA reader with 570 nm filter.
TransJection
Transfection was carried out using Lipofectin technique as
described previously (Boucraut et al., 1991). Briefly, 0.5 x 106
of exponentially growing adherent cells (in 25 cm2 flask) were
washed with sterile phosphate buffered saline (PBS) followed
by addition of 5 ml of Optimem. Cells were incubated for 4 h
at 37C. This was followed by the addition of genomic DNA
containing 21g Ll-l of P2-m gene and 2 jig il`1 of marker
gene i.e. pSV2neo, which were added to 50 gl of PBS and
2.5 ml of Optimem in a bijoue tube. The content of this tube
was added very gently to a second bijoue tube containing
150 1l of Lipofectin and 2.5 ml of Optimem. This mixture
was then added to the culture flask previously treated with
the Optimem.
Cells were incubated overnight at 37°C after replacing the
medium with fresh RPMI containing 10% FCS and the
incubation continued for a further 10 h. The supernatant was
then replaced by fresh medium containing Geneticin (500 ig
ml-', Sigma) the concentration found to be sufficient to kill
100% of untransfected cells during the first weeks ofculture).
After 2 weeks of culture the surviving cells were cloned and
positive clones were selected using W6/32 as a marker in
peroxidase staining technique.
Results
Time course
The time course of LAK/NK killing against tumour targets
was investigated, a representative of which is shown in
Figure 1. At 20/1 and 10/1 E/T ratios after 10 days of culture
there was a significant decrease in the level of cytotoxicity
with time suggesting the inverse relationship between the
degree of LAK/NK killing and duration of effector cell
culture.
Investigation ofcorrelation betiveen the levels ofclass I antigen
expression and LAKINK killing
In order to establish whether the intensity of class I antigen
expression on tumour targets affects their susceptibility to
LAK/NK killing, parallel binding and killing experiments
were carried out on 14 cell lines. As can be seen from Table
1, there was a varying degree of class I antigen expression on
tumour targets ranging from complete negative (cpm below
100 like Tera I and Fen) to highly positive line SKV14
E/T ratios 20/1 LII
10/1 -
2 3 4 7 16 21
Number of days in culture
Figure 1 Time course of cytotoxic activity of IL-2-activated LAK/NK of an individual against Fen cell line.
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Table I LAK/NK activity of IL-2-activated MNCs on cell lines
expressing different intensity of class I antigens
LAK/NK killing EIT ratios
Lines Class I 20/1 10/1 5/1
J82 2,064 407 2 1 1
SKVl4 1,627 288 11 17 -2
Wil 1,208 67 14 2 ND
MCF7 1,186 77 28 22 16
A431 1,121 110 15 -2 7
5637 1,118 110 -1 1 -2
T47D 1,105 77 59 43 31
RT112 1,026 57 -9 1 -16
Scaber 920 109 0 -1 -20
Lan 749 76 2 7 16
Ep2102 706 54 36 35 33
RT4 566 61 -20 -17 10
Tera II 207±26 34 28 18
Fen 86 12 77 62 52
Tera I 70±21 26 20 11
r -0.23 -0.30 -0.47
P 0.39 0.27 0.08
Results are expressed in mean ± s.d. (c.p.m.) of three replicates for
class I antigens and in percent specific for LAK/NK. r and P denote
Spearman correlation value and significance level between the class I
antigens and the degree of killing. ND denotes not done.
(1,627 ± 288 cpm). The LAK/NK activity varied from target
to target and when assessed using the Spearman-Rank cor-
relation coefficient, there was no statistically significant cor-
relation between the class I antigen and efficiency of killing at
20/1 and 10/1 and 5/1 E/T ratios (Table I). However,
significant killing of tumour lines expressing lower class I
antigens was observed when LAK/NK cells were tested against
different targets at lower E/T ratios (Table II). Correlation
with class II antigens after IFNTy (100 u ml-') stimulation of
the target cells was less informative (Table III) and even after
splitting the cells into higher and lower inducer there was no
significant correlation with LAK/NK killing.
Correction ofmissing class I antigen and its effects on
efficiency ofLAK/NK killing
If the intensity of class I antigen expression is an important
factor for LAK/NK killing, the introduction of missing class
I antigens into a class I negative tumour target ought to
decrease their susceptibility to LAK/NK killing. In our pre-
vious study we have demonstrated that bladder cell line Fen
lacks P2 microglobulin (Nouri et al., 1992b). After transfec-
tion with the missing 132m gene and selection with Geneticin,
positive and negative cell clones were expanded and tested
for susceptibility to LAK/NK killing. As can be seen from
Table IV the level of binding for class I antigens before and
after transfection were 132 ± 20 and 2,000 ± 48 cpm respec-
tively. At higher E/T ratios (20/1) the restoration of class I
antigens did not have a significant protective effects on LAK/
NK killing (36% vs 45% respectively). However, at low E/T
ratio 1/1 the restoration of class I expression was associated
with less killing.
Effects ofcytokines on target cells
Cytokines like interferons are known to upregulate MHC
antigens. Experiment was set up to investigate the changes in
the susceptibility of class I negative tumour target Fen after
48 h of IFN stimulation. As can be seen from Figure 2, there
was a significant increase in the susceptibility of the cells in
response to IFNs. The percent increase in the killing for E/T
ratios of 20/1 and 10/1 for IFN a, P and y treated cells were
30, 47, 44 and 6, 20 and 18 respectively indicating that all
three IFNs increase susceptibility of target cells to killing. In
addition, it was also found that the effector cell treatment
with these IFNs increased their killing potential (Figure 3).
This resulted in an increase of up to 20% over and above
that with IL-2 alone and this may be a factor for their
Table II Percent cytotoxic killing of LAK/NK of different
individuals against a number of tumour targets
E/T ratios
Target Effector 20/1 10/1 5/1
Fen 1 34 10 0
(a) 2 56 46 40
3 79 81 68
4 16 12 14
5 76 63 52
6 64 48 38
Tera I 1 30 34 23
(a) 2 83 71 60
3 60 52 45
4 10 8 6
5 60 20 10
Tera II 1 34 29 18
(b) 2 31 15 12
3 30 15 13
4 30 12 10
J82 1 5 nd nd
(c) 2 6 8 4
3 nd 1 2
4 24 nd nd
RT112 1 32 8 nd
(c) 2 3 2 6
3 12 7 16
4 4 2 4
Results are expressed in mean± s.d. nd denoted not done,
a = class negative lines (c.p.m. < 100), b = intermediate class I
expressor (207 c.p.m.) and c = high class I expressor (2,06 and 1,026
c.p.m.).
Table III Correlation between efficiency of LAK/NK killing and
inducibility of MHC antigen induction in resopnse to IFNy
IFNy LAKINK killing E/T ratios
Lines Class II 20/1 5/1
T47D 1,575± 174 59 31
SKV14 1,484± 183 11 -2
Fen 1,337± 34 77 52
Wil 1,227± 118 14 1
J82 1,020± 112 2 1
MCF7 960± 114 28 16
Tera I 677± 90 26 11
Scaber 619±24 1 -20
RT112 261± 28 -9 -16
RT4 212± 92 -20 10
Ep2102 130± 32 36 33
Tera II 93± 26 34 18
Lan 89± 22 2 6
r 0.34 -0.02
P 0.25 0.93
Results are expressed as mean ± s.d. (c.p.m.) of three replicates.
ND, r and P denote, not done, Spearman correlation values and
level of significance respectively.
Table IV LAK/NK killing on Fen cell line before and after gene
transfection
E/T ratios Non-transfected Transfected
20/1 36 45
10/1 45 51
5/1 41 52
2.5/1 26 48
1/1 31 10
Class I antigens 132 ± 20 2,000 ± 48
Results of class I antigen binding and LAK/NK killing activity are
expressed in mean ± s.d. of three replicates (in c.p.m.) and percent
killing respectively.
therapeutic efficacy of these cytokines.
In a separate experiment, in which the target cells were
pretreated with IFNy 48 h prior to testing, monoclonal
antibodies against class I (W6/32) and class II (HB55) were
added to investigate their influence of the LAK/NK killing.1226 A.M.E. NOURI etal.
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Figure 2 Increased susceptibility of Fen cell line by Interferon
treatment to cytotoxic activity of IL-2-activated LAK/NK Cells.
As can be seen from Table V. The addition of both anti-
bodies increased the target killing by as much as 18%
indicating that the increase target killing by anti-class I
antibody is not class I antigen specific and may be due to the
FcR-mediated killing.
Discussion
The results of this investigation have demonstrated that there
was a large variation in the efficiency of LAK/NK killing of
different individuals against the same tumour target and the
same individual against different targets and this was at its
maximum during the first week to 10 days of culture. The
results also demonstrated that there was no inverse correla-
tion between the LAK/NK killing and the intensity of class I
antigen when the cytotoxicity assay was performed at high
E/T ratios whereas at lower E/T ratios the class I negative
tumours were found to be better targets.
Specific CTL was discovered long before LAK/NK cells
and shown to be restricted by MHC class I antigens (Zinker-
nagal et al., 1979). NK in contrast, were only discovered
from what were thought to be false positive reactions in
negative controls for CTL assays (Carlson & Wegman 1977).
The specificity of CTL were refined by T cell cloning and
shown to use the alpha/beta dimer of the T cell receptor
(TCR, McMichael et al., 1988; Moss et al., 1991) and, unlike
LAK/NK activity (Gorelik et al., 1988), could be inhibited
by antibodies to HLA class I (Salter et al., 1989). The
demonstration that cloned MHC restricted tumour infiltrat-
ing lymphocytes from melanomas could circulate and home
to metastases in association with their rejection (Rosenberg
et al., 1990) is to date the most convincing evidence that
Figure 3 Enhancement of cytotoxic activity of IL-2-activated
cells by Interferons tested against Fen tumour cell line.
Table V Effect of monoclonal antibody addition on the efficiency of
LAK/NK killing
E/T ratios NT + HBS5 7 + W6/32
A
10/1 54 62 63 72
5/1 47 50 56 63
B
20/1 23 25 19 33
10/1 15 12 8 9
Results are expressed in % specific killing. Effector cells from two
individuals (A and B) were mixed with target cells pre-treated with
IFN y for 48 h. Antibodies W6/32 (anti-class I) and HB55 (anti-class
II) were added in 100 LIl at the beginning of 4h killing period.
anti-tumour immune specificity exists in man.
LAK/NK, were originally referred to as NK and were
found to exist spontaneously in peripheral blood without the
need for preactivation (Gorelik et al., 1988). However, when
recombinant cytokines and particularly IL-2 became avail-
able and the cytotoxic cells induced found to be more active
against tumours such as Daudi which were consistently nega-
tive with NK cells they were given a separate name i.e.
Lymphokine Activated Killers or LAK (Grimm et al., 1982).
However more recent research using lymphocyte
differentiation markers and studies of their cytotoxic
mechanism suggest that LAK/NK are probably the same cell
(Lange et al., 1991) and the differential cytotoxicity may only
reflect the degree of activation or differentiation from a
common stem cell.
The results of this paper have demonstrated that at high
E/T ratios LAK/NK activity does not show an inverse cor-
relation with the degree of class I loss as has been demon-
strated by some authors (Lobo & Spencer 1989; Maziarz et
al., 1990) and that the correction of these antigens by
cytokine treatment or transfection does not alter LAK/NK
activity.
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Our findings support the views of Pena et al. (1989) who
demonstrated that the efficiency of LAK/NK killing was
independent of MHC class I antigen expression, and those by
Aosi et al. (1991) who demonstrated that restoration of
MHC class I antigens by addition of exogenous immuno-
genic peptides did not effect the efficiency of NK killing on
target cells expressing both heavy and light chains of class I
antigens but were negative with W6/32 antibody.
A possible explanation for these conflicting results, which
might also explain why our data at low E/T ratio did show
an inverse correlation between HLA class I level and LAK/
NK cytotoxicity (Table I) was reported by Storkus et al.
(1991). They demonstrated that transfection of some poly-
morphic class I genes such as HLA-A3, HLA-B7 and HLA-
B27 into a class I negative tumour cell line had a protective
effect on NK lysis, whilst other such as HLA-A2 did not,
suggesting that conformational structure of different poly-
morphic class I antigens may influence the efficiency of its
blocking effect on NK killing.
Our working hypothesis in explaining the contradictory
reports is that the over-riding factor for controlling the non-
MHC restricted LAK/NK killing is a receptor/target inter-
action independent of the mechanism regulating class I
expression. However under circumstances when receptor ex-
pression is low, certain class I molecules as demonstrated by
Storkus et al. (1991) would have conformational masking
effect, hence becoming the limiting factor for the killing. On
the other hand when receptors are in excess LAK/NK lysis
occurs whatever the level of class I expression.
As yet the clinical relevance of these cells is unclear and
their role in resistance to cancer is still controversial. While
there was some suggestion that they were clinically significant
from the studies of Rosenberg et al. (1989) whose clinical
trial in melanoma demonstrated that IL-2 plus LAK/NK was
more effective than IL-2 alone in terms of durable complete
remission, his results in renal cell cancer were not significant
and overview of pooled results in renal cell cancer failed to
demonstrate any advantage of combination therapy over the
results from IL-2 alone (Oliver & Nouri, 1992).
To better clarify our uncertainty about the role of LAK/
NK in vivo, more work including specific blocking and
augmentation experiments in vitro and in vivo are needed to
identify the target recognition molecules and receptor
mechanism involved.
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